{
    "nctId": "NCT02773004",
    "briefTitle": "Prospective Study Assessing EndoPredict\u00ae Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer",
    "officialTitle": "Prospective Multicenter Study Assessing EndoPredict\u00ae (EP) Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer With Uncertainty on the Indication of Chemotherapy Using Standard Assessments",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 203,
    "primaryOutcomeMeasure": "The proportion of patients whose choice of treatment is changed as a result of receiving the EPclin genomic test result",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years,\n* Performance status 0 or 1,\n* Patient with newly diagnosed, previously untreated, unilateral, localized, histologically confirmed, invasive breast cancer\n* Fully operated breast cancer including complete resection of breast tumor and adequate axillary surgery\n* Available surgical material (formalin-fixed, paraffin-embedded) for EPclin\u00ae evaluation\n* ER-positive by IHC (\\>10% cells stained or Allred Score\u22654)\n* HER2-negative by IHC (score 0 or 1+) and/or Fish/Cish\n* Node-negative or pN1mi (through axillary lymph node examination using sentinel node biopsy or axillary clearance)\n* Uncertainty regarding the toxicity/benefit of adjuvant chemotherapy, outlined inthe following situations:\n\n  * Lobular histology\n  * Or grade II\n  * Or grade III and pT \\< 2cm\n* Adequate renal, hepatic, cardiac and hematopoietic functions for a chemotherapy administration\n* Willingness and ability to comply with scheduled visits as well as with test results and chemotherapy decision according to the latest\n* Signed informed consent and Health insurance coverage\n\nExclusion Criteria:\n\n* Non operable, bilateral, locally advanced, T4 or metastatic breast cancer\n* Any lymph node involvement with the exception of pN0i+ or pN1mi\n* HER2 Overexpression\n* Diagnosis of any previous malignancy within the last 5 years, except for adequately treated basal cell carcinoma, or squamous cell skin carcinoma, or in situ cervical carcinoma\n* Any previous systemic or locoregional treatment for the present breast cancer\n* Documented inherited predisposition with BRCA1/2 or TP53 mutation\n* Previous hormone replacement therapy (HRT) stopped less than 2 weeks before surgery\n* Previous treatment for the present breast cancer\n* Person unable to give informed consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}